Corcept Therapeutics Receives FDA Setback for Relacorilant, Faces Investor Scrutiny and Legal Investigations

Corcept Therapeutics Faces Regulatory Setback with FDA’s Complete Response Letter

Corcept Therapeutics Incorporated encounters a significant regulatory hurdle as it receives a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its proposed treatment for hypercortisolism, relacorilant. The CRL, issued on December 31, 2025, indicates that while the FDA acknowledges the results from Corcept’s pivotal GRACE trial, further evidence is required to establish the drug's effectiveness adequately. This unexpected feedback comes despite Corcept's previous assurances to investors about relacorilant's potential for clinical success and its anticipated annual revenue generation of $3 billion to $5 billion within a few years of market approval.

The stark contrast between Corcept's optimistic projections and the FDA's assessment raises serious questions about the company's communication with its stakeholders. Prior to the CRL, Corcept expressed confidence that its New Drug Application (NDA) was on track for approval by the end of 2025, leading many investors to believe in a positive trajectory for the company's growth in the hypercortisolism market. However, the FDA's findings suggest that the benefits of relacorilant may not sufficiently outweigh its risks at this stage, prompting concerns about whether the company may have overstated the drug's commercial viability.

In light of these developments, law firms such as Hagens Berman and Schall Law Firm have initiated investigations to determine whether Corcept misled investors regarding the efficacy and market potential of relacorilant. Reed Kathrein from Hagens Berman emphasizes the necessity of evaluating if the company provided misleading information that could have contributed to the drastic share price decline of over 50%—a loss of more than $3.6 billion in market capitalization within a single day. Both firms are reaching out to affected shareholders, urging them to share information and consider legal recourse in light of this significant setback.

In addition to the ongoing investigations, Corcept Therapeutics now faces the challenging task of addressing the FDA's concerns and potentially revising its clinical strategy for relacorilant. This setback serves as a reminder of the complexities and unpredictability inherent in drug development, especially in a competitive therapeutic landscape. The outcome of the additional evidence required by the FDA will not only impact Corcept's future prospects but also the landscape for treatments aimed at hypercortisolism, where patient needs continue to grow.